GSK lung cancer treatment data shows "positive anti-tumour activity"
(Alliance News) - GSK PLC on Monday set out its first batch of global data for the risvutatug rezetecan drug.
The London-based biopharmaceutical and biotechnology company said the drug would help patients with advanced-stage small cell lung cancer, with findings showing "positive anti-tumour activity".
Results from the phase Ib dose-optimisation part of the Embold PanTumour-101 trial showed ris-rez had an objective response rate of 61% among patients taking an 8 milligrams per kilogram dose, compared to 32% at 6mg/kg, GSK said.
The objective response rate is the percentage of patients whose cancer shrinks or disappears entirely.
Senior Vice President, Global Head of Oncology, R&D, GSK Hesham Abdullah said, "Today's first global data for Ris-Rez build on the statistically significant overall survival benefit recently reported in Hansoh’s pivotal Chinese trial. As the data for Ris-Rez continues to grow, we remain focused on accelerating development in extensive-stage small cell lung cancer, where patients often relapse quickly and urgently need more treatment options."
Small cell lung cancer is characterised by "early metastatic spread, frequent relapse and poor prognosis," the company said. Survival of patients with standard treatments is around 12 to 13 months, with the cancer accounting for about 10-15% of all lung cancer diagnoses globally.
Shares in GSK were marginally higher at 1,863.00 pence per share on Monday morning in London.
By Niall Holden, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
10 Best Blue-Chip Stocks to Buy for the Long Term
This 1-Star Stock Trades at a 94% Premium. Is It Time to Sell?
United States